Sign in to view content

Impact of Faricimab vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes With DME in the YOSEMITE/RHINE Phase 3 Trials

Glenn J. Jaffe, MD

Video
Published 2023

Related

Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022
ASRS Updates in the Management of Diabetic Retinopathy DME and PDR in the Middle East and Africa
Sunir J. Garg, MD, FACS, FASRS
Webinars and Journal Clubs
2023
The Functional Burden of Diabetic Retinopathy in the United States – How Ranibizumab May Shift Treatment Paradigms
Jeffrey R Willis, MD/PhD
On Demand Cases, Courses, and Papers
2017

Category: Macular Pucker - Epiretinal Membrane

See more